中国创新药企以一系列亿美元级别授权交易、成功IPO和强劲研发管线点燃了投资热情,正在迎来自己的“DeepSeek时刻”。从盈利到BD爆发,中国创新药行业的“DeepSeek”时刻已至?今年以来,暴涨超60%,超越AI板块17%的涨幅。这股热潮背后,是中国创新药企以一系列亿美元级别授权交易、成功IPO和强劲研发管线点燃了投资者热情。数据显示,2025年第一季度,中国药企参与的并购与授权交易总值翻倍至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.